HCPLive Network

FDA Approves Zecuity Skin Patch to Treat Migraine

 
TUESDAY, Jan. 22 (HealthDay News) -- Zecuity, a sumatriptan iontophoretic single-use, battery-powered transdermal system, has been approved by the U.S. Food and Drug Administration for acute treatment of migraine with or without aura in adults.

Noting that migraine patients often present with additional symptoms including migraine-related nausea, Zecuity patches provide an non-oral route of administration. Zecuity patches are applied to the upper arm or thigh and, on activation, initiate transdermal delivery of 6.5 mg sumatriptan over a four-hour period.

The safety and effectiveness of Zecuity were assessed in phase 3 trials that included more than 800 patients who used more than 10,000 patches. After two hours, 18 percent of patients who used Zecuity patches had no more headache, 53 percent experienced some headache relief, and 84 percent had no more nausea. For patients who used a placebo patch, the corresponding figures were 9, 29, and 63 percent. Side effects included application site pain, tingling, itching, and discomfort (5 percent), and triptan-associated adverse events (atypical sensations, 2 percent; pain and other pressure sensations, 2 percent).

"Migraine-related nausea can be as debilitating as migraine headache pain itself," study investigator Stephen D. Silberstein, M.D., of the Jefferson Headache Center in Philadelphia, said in a statement. "Treatments bypassing the gastrointestinal tract may be the best way to treat these patients."
 

More Information

Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
Research indicates that patients with type 2 diabetics mellitus and low testosterone levels are 6 times more likely than those with normal testosterone levels to have increased carotid artery intima media thickness (CIMT) and decreased endothelial function.
Distal radius fracture—also called a wrist fracture by patients—is common. Its incidence is expected to increase in the next 20 years, since our population is aging and the risk of this specific fracture increases in patients with metabolic disorders, including osteoporosis. However, the health care community has yet to reach a consensus regarding indications for surgery, and there is insufficient data to identify a preferred operative technique.
Team-based feedback has the potential to improve surgeons’ relationships with coworkers and patients. The clinical implication: using such feedback to improve less-than-optimal behaviors could increase practice reimbursement under the “pay-for-professionalism” system.
More Reading